Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Feedcolon + mesalamine is a combination drug product containing two active ingredients. Mesalamine (also known as 5-aminosalicylic acid or 5-ASA) is an anti-inflammatory agent used primarily to treat and prevent flare-ups of mild to moderately active ulcerative colitis, an inflammatory bowel disease affecting the colon. It works by exerting a topical anti-inflammatory effect on the colonic epithelial cells, likely through inhibition of cyclooxygenase and lipoxygenase pathways, thereby reducing prostaglandin and leukotriene production in the colon[1][2][6][7]. The specific identity and pharmacological role of "Feedcolon" are not established in major medical databases or literature; it may be a regional brand name or proprietary formulation combined with mesalamine for gastrointestinal use. Without further information about "Feedcolon," only the properties of mesalamine can be described with certainty.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Feedcolon + mesalamine.